Hypervision Surgical
Latest round
- Series A
Last raised
- Apr 2026
Total raised
- $31M
Investors
- 10
About Hypervision Surgical
Based in London, UK, and co-founded by Michael Ebner (CEO), Tom Vercauteren (CSO), Sébastien Ourselin (Board Director), and Jonathan Shapey (clinical need) in 2020 as a spin-out company of King's College London, Hypervision Surgical Ltd operates as a Healthcare IT company. The company provides advanced computer-assisted tissue analysis technology, using AI (artificial intelligence) powered hyperspectral imaging. The company offers real-time, wide-field tissue information that enhances surgical precision and patient safety. Hypervision Surgical's technology utilizes non-contact, non-invasive optical imaging that does not require any contrast agents. They employ AI algorithms to provide quantitative tissue analysis, including perfusion assessment and tissue differentiation in real-time. Hyperspectral imaging splits light into multiple spectral bands beyond what the human eye can perceive, enabling objective tissue characterization. This tissue information is crucial for guiding surgical procedures effectively. Hypervision generates revenue through sales of its hyperspectral imaging hardware systems, including the HYPERSNAP platform, deployed in surgical environments. Additional revenue is derived from software subscriptions and licensing of its AI-powered analytics platform, providing real-time intraoperative insights. The company may also generate income through service agreements, clinical integration partnerships, and collaborations with medical device manufacturers and healthcare providers seeking advanced surgical imaging and data-driven decision support solutions. Hypervision plans to scale its Hyperspectral Intelligence platform across clinical environments by increasing adoption in hospitals and integrating its technology into laparoscopic, robotic, and minimally invasive surgical systems. The company will continue advancing its next-generation spectral sensing technology in collaboration with imec, while expanding its cloud-enabled analytics capabilities. Growth is expected through broader commercial deployment, regulatory expansion, and positioning the platform as a data-driven standard for real-time intraoperative decision-making.
Who invested in Hypervision Surgical
10 investors across 2 rounds
See all investors in Hypervision Surgical
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hypervision Surgical
Who invested in Hypervision Surgical?
Hypervision Surgical has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hypervision Surgical raised?
Hypervision Surgical has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Hypervision Surgical last raise money?
Hypervision Surgical's most recent round on record is a Series A, in Apr 2026.
What does Hypervision Surgical do?
Based in London, UK, and co-founded by Michael Ebner (CEO), Tom Vercauteren (CSO), Sébastien Ourselin (Board Director), and Jonathan Shapey (clinical need) in 2020 as a spin-out company of King's College London, Hypervision Surgical Ltd operates as a Healthcare IT company.
Where is Hypervision Surgical headquartered?
Hypervision Surgical is headquartered in London, UK.
Which VCs invest in companies like Hypervision Surgical?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back healthcare it companies at Hypervision Surgical's stage. Their profiles are linked below.
VCs backing healthcare it startups at Series A
Raising like Hypervision Surgical? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.